Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

TxCell Granted Five New Patents in Major Global Territories

Published: Wednesday, August 27, 2014
Last Updated: Wednesday, August 27, 2014
Bookmark and Share
Latest US patent key to TxCell’s innovative personalized cellular therapy business model.

TxCell SA has announced that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014.

These five new patents cover an important part of TxCell’s core technology and ASTrIA platform. These patents strengthen TxCell’s intellectual property positioning and competitive advantage.

The most recent patent, US 881553, has been granted in the USA on August 26 2014. This patent is for the TxCell method of assessing the efficacy of an antigen-specific Type 1 Treg cell therapy in a patient. The patent is a key asset for the company as it forms an important part of TxCell’s innovative business model.

The ability to use this method to determine responder from non-responder patients after the first administration of TxCell’s cellular immunotherapies would further increase the value of TxCell technologies and as a result, provide a powerful tool in future discussions with payers. TxCell will use this method during the forthcoming phase IIb clinical study with the company’s lead product Ovasave® in severe refractory Crohn’s disease patients.

The patent JP 5502322 granted in Japan describes a method for the isolation of a food- or auto-antigen specific Type 1 Treg cell population. This Japanese patent is, as well, of strategic importance for TxCell as it protects the first step of the TxCell proprietary manufacturing process for making unique personalized cellular immunotherapies.

The further patents granted are respectively for use of antigen specific Type 1 Treg cell populations for treating multiple sclerosis, granted in China, and for the use of pharmaceutical compositions comprising Type 1 Treg cells and mesenchymal stem cells in combination, granted in Japan and Australia.

"TxCell has dedicated years of effort in research and development to establish a robust intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need that are waiting for innovative therapeutic options," said Damian Marron, Chief Executive Officer of TxCell. “We believe these valuable new patents are an essential addition to our patent collection. TxCell now owns or controls a total of more than 140 granted patents in the field of antigen-specific Treg cell-based therapy, with dozens of additional patents pending. These will provide the company with very strong protection for its ASTrIA platform and portfolio of cellular immunotherapy treatments. We will continue to actively patent new discoveries to further protect and extend our innovative technology and products.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
TxCell to Present at the Cell & Gene Therapy Forum 2015
Company to present its experience with Cell Therapy at the Cell & Gene Therapy Forum 2015, Washington.
Saturday, January 24, 2015
TxCell to Lead POSITIVE Project to Automate First Production Step of Ovasave®
Grant of over EUR 400,000 awarded by the Conseil Régional Provence-Alpes-Côte-D’azur to the consortium of TxCell, Gene and Cell therapy Unit, Nice (UTCG) and Biosafe.
Saturday, July 05, 2014
TxCell Granted Certificate of GMP Compliance for Cell Therapy Manufacturing Facility
Confirmation of quality of TxCell’s manufacturing platform by ANSM enables regulatory submissions for Ovasave® phase IIb clinical study.
Friday, June 13, 2014
TxCell Obtains Manufacturing Accreditation Status
Company receives accreditation from ANSM for its French cell therapy manufacturing facility.
Wednesday, December 04, 2013
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos